Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.61 |
| ▸ | DPP8 | Q6V1X1 | 12/20 | 0.61 |
| ▸ | DPP9 | Q86TI2 | 12/20 | 0.61 |
| ▸ | DPP7 | Q9UHL4 | 11/20 | 0.61 |
| ▸ | FAP | Q12884 | 11/20 | 0.61 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21411220 | 1.00 | DPP4 (0.61) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL22255191 | 0.83 | DPP4 (0.53) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL21410996 | 0.81 | S1PR1 (0.51) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL23211355 | 0.81 | S1PR1 (0.51) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL23211432 | 0.80 | DPP4 (0.50) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL23211434 | 0.80 | DPP4 (0.50) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL28499545 | 0.78 | ALDH1A1 (0.50) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL29910014 | 0.78 | ALDH1A1 (0.50) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL23211486 | 0.77 | DPP4 (0.57) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL23211484 | 0.77 | DPP4 (0.57) | DPP4DPP8DPP9DPP7FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174685-A1 | OX2R Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-30 | — | — | US | disclosed |
| US-11905297-B2 | OX2R compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-02-20 | — | — | US | disclosed |
| US-20230122024-A1 | OX2R Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-04-20 | — | — | US | disclosed |
| US-11479560-B2 | OX2R compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2022-10-25 | — | — | US | disclosed |
| US-11472813-B2 | OX2R compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-10-18 | — | — | US | disclosed |
| US-20210163494-A1 | OX2R Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210107914-A1 | OX2R Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-04-15 | — | — | US | disclosed |
| CN-112165940-A | OX2R compound | 德克萨斯州立大学董事会 | 2021-01-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479560-B2 | OX2R compounds | HCRTR2, HCRTR1, OXTR | DPP4 4445/4885DPP8 4182/4885DPP9 4589/4885 |
| US-11905297-B2 | OX2R compounds | HCRTR2, HCRTR1, OXTR | DPP4 4445/4885DPP8 4182/4885DPP9 4589/4885 |
| US-20240174685-A1 | OX2R Compounds | HCRTR2, HCRTR1, OXTR | DPP4 4445/4885DPP8 4182/4885DPP9 4589/4885 |
| US-20210107914-A1 | OX2R Compounds | HCRTR2, HCRTR1, OXTR | DPP4 4445/4885DPP8 4182/4885DPP9 4589/4885 |
| US-20230122024-A1 | OX2R Compounds | HCRTR2, HCRTR1, OXTR | DPP4 4445/4885DPP8 4182/4885DPP9 4589/4885 |
| US-11472813-B2 | OX2R compounds | HCRTR2, HCRTR1, OXTR | DPP4 4445/4885DPP8 4182/4885DPP9 4589/4885 |
| US-20210163494-A1 | OX2R Compounds | HCRTR2, HCRTR1, OXTR | DPP4 4445/4885DPP8 4182/4885DPP9 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.